Physician profile
Jonathan H Abiera
NPI 1689055451
$5,153.99
in general payments reported to CMS, 2019-2025
36 companies · $2,333 in 2025
The $2,333 reported for 2025 was more than what 86% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $143 · 2021: $434 · 2022: $721 · 2023: $383 · 2024: $845 · 2025: $2,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,180 · Travel and Lodging: $1,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,179.70 |
| Travel and Lodging | $1,381.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $2,406.02 | 2022-2025 | Pico, Collagenase Santyl, Grafix |
| Stryker Corporation | $473.44 | 2019-2024 | Invision, Prophecy, Inbone |
| Abbvie INC. | $325.05 | 2021-2024 | |
| Integra Lifesciences Corporation | $267.21 | 2019-2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Kerecis Limited | $180.84 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Medtronic, INC. | $150.31 | 2024 | Intellis Adaptivestim |
| Novo Nordisk INC | $139.84 | 2019-2023 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $110.08 | 2020-2024 | Gardasil 9, Gardasil, Vaxelis |
| Reapplix INC. | $98.17 | 2025 | 3c Patch Kit - Box |
| Abbott Laboratories | $86.41 | 2021-2022 | |
| Convatec INC. | $84.35 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.20 | 2022-2023 | Xifaxan |
| Dexcom, INC. | $80.57 | 2021-2022 | |
| Organogenesis INC. | $73.06 | 2019-2024 | Puraply |
| Orthofix Medical, INC. | $71.96 | 2021-2025 | Physio-Stim |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.91 | 2021-2023 | Jardiance |
| Derma Sciences, INC. | $49.10 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.56 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.59 | 2019-2021 | |
| Amarin Pharma, INC. | $31.85 | 2021 | |
| Horizon Therapeutics Plc | $29.13 | 2019 | |
| Solventum Corporation | $28.98 | 2024 | Snap, Promogran Prisma, Activ.A.C. |
| Eisai INC. | $26.73 | 2021 | |
| Treace Medical Concepts, INC. | $20.59 | 2023 | |
| Paragon 28, INC. | $19.35 | 2020-2022 | |
| Bioventus LLC | $18.75 | 2023 | |
| Idorsia Pharmaceuticals US INC | $16.28 | 2024 | Quviviq |
| Paratek Pharmaceuticals, INC. | $15.93 | 2021 | |
| Nevro Corp. | $15.23 | 2021 | |
| Kci USA, INC. | $14.75 | 2020 | |
| Amgen INC. | $14.72 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $14.13 | 2019 | |
| Celgene Corporation | $13.91 | 2019 | |
| Allergan, INC. | $12.85 | 2019 | |
| Misonix INC | $12.30 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Abiera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.